Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study

Xiying Shao; Yabing Zheng; Wenming Cao; Xiabo Shen; Guangliang Li; Junqing Chen; Yuan Huang; Ping Huang; Lei Shi; Weiwu Ye; Weibin Zou; Caijin Lou; Lei Lei; Jian Huang; Zhanhong Chen; Xiaojia Wang

doi:10.21037/atm-21-1340

Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study

Ann Transl Med. 2021 Apr;9(8):707. doi: 10.21037/atm-21-1340.

Authors

Xiying Shao^{1

2}, Yabing Zheng^{1

2}, Wenming Cao^{1

2}, Xiabo Shen^{1

2}, Guangliang Li^{1

2}, Junqing Chen^{1

2}, Yuan Huang^{1

2}, Ping Huang^{1

2}, Lei Shi^{1

2}, Weiwu Ye^{1

2}, Weibin Zou^{1

2}, Caijin Lou^{1

2}, Lei Lei^{1

2}, Jian Huang^{1

2}, Zhanhong Chen^{1

2}, Xiaojia Wang^{1

2}

Affiliations

¹ Department of Medical Oncology (Breast Cancer), Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Hangzhou, China.
² Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, China.

Abstract

Background: Palbociclib combined with endocrine therapy has been approved as a front-line treatment for hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC). A key challenge remains to uncover biomarkers to identify those patients who may benefit from palbociclib treatment.

Methods: We retrospectively analyzed the values of Ki67 and progesterone receptor (PR) as detected by immunohistochemistry in 81 ABC patients with palbociclib and hormone therapy treatment, and evaluated the impact on progression-free survival (PFS).

Results: In the total population, women with Ki67 ≥14% had marginally significantly shorter PFS than those with Ki67 <14% (P=0.062). Patients with Ki67 ≥30% had significantly shorter PFS than those with Ki67 <30% (P=0.048). Meanwhile, PR ≥20% was associated with longer PFS. Moreover, the change of Ki67 or PR from primary tissue to metastatic lesions was related to PFS. As for the hormone therapy subgroup, there were significant associations between Ki67 and PR levels and PFS in the aromatase inhibitors (AIs) subgroup. Patients with Ki67 ≥14% or Ki67 ≥30% had shorter PFS than those with Ki67 <14% or Ki67 <30%, respectively (P=0.024, P<0.001). Additionally, the change of Ki67 or PR from primary tissue to metastatic lesions was related to PFS. When both Ki67 and PR were considered, there were significant differences between the different cohorts. Compared with patients with Ki67 ≥14% and PR <20%, those with Ki67 <14% and PR ≥20% had significantly longer PFS. In addition, patients with Ki67 <30% and PR ≥20% had significantly longer PFS than those with Ki67 ≥30% and PR <20%. Furthermore, in the AI cohort, patients with Ki67 <14% and PR ≥20% had significantly longer PFS than those with Ki67 ≥14% and PR <20%. Women with Ki67 <30% and PR ≥20% had significantly longer PFS than those with Ki67 ≥30% and PR <20%.

Conclusions: The present study indicates that both Ki67 and PR have great impacts on palbociclib and hormone therapy and may contribute to selecting more effective partners for palbociclib.

Keywords: Ki67; palbociclib; progesterone receptor.